DEKA
31.1.2024 16:01:35 CET | Business Wire | Press release
DEKA, an Italian subsidiary of the El.En. Group, listed on the Eurostar Next of Borsa Italiana (ELN.MI), specialized in the development and production of pioneering Energy Based devices for aesthetics and surgery, on the occasion of the 25th IMCAS World Congress, which will be held in Paris from February 1-3, has announced the launch of 4 new laser platforms which integrate the “PRO” line, presented during the World Congress of Dermatology (WCD) held in Singapore last July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131482600/en/
(Photo: DEKA)
After the success obtained in the US and Canada, DEKA, with its laser systems, among which the very famous lunch-time CoolPeel® treatment for face rejuvenation, and epilation is now introducing the TETRA PROTM, MOTUS PROTM, SMARTXIDE PROTM and TOROTM platforms to the market.
With these new solutions DEKA transforms traditional dermatology laser technology paradigms, aesthetic medicine and dermatologic surgery, opening them to new practical frontiers.
Riccardo Stocchi – The company’s Innovation Manager stated: “The enthusiasm for the success we obtained with the PRO line and the ability to anticipate physicians’ requests, have turned, once again, into DEKA’s ability to create innovation, paying close attention to product positioning and correct segmentation of the reference market, responding with breakthrough technologies, which provide enormous benefits to both operators and patients. The road marked by DEKA, which has invested substantially in research and development and clinical research, obtaining extraordinary results, highlights, besides high efficacy and safety standards, maniacal attention to detail, from equipment design to software usability, with more and more innovative graphic user interfaces, which are absolutely intuitive and user friendly".
Paolo Salvadeo, DEKA’s CEO and El.En.’s General Manager, echoes Mr. Stocchi by adding: "These four new laser solutions, which see the light after few months from the launch of the PRO line, are the umpteenth demonstration of the efficacy of our organizational and R&D model. The path is marked. Thanks to DEKA’s strong aid, our group, in the medical segment, not only wishes to assert itself as the first player in the medical laser segment worldwide, but also to prospectively maintain a strong leadership position with regard to the market and competition. It is a fast-running machine, which we have no intention of slowing down".
Talking specifically about the four DEKA novelties, TETRA PROTM carries on the success seen by the birth of the “CoolPeel®” treatment/phenomenon in the US. TETRA PROTM, with its 40W of power, is the evolution of the 30W “SmartXide Tetra” CO2 laser, with a broader scanning area and treatment time reduction by 25%. The new “TETRA MOVEO” scanning mode also allows for treatment time reduction of the Made in the USA “CoolPeel®”. The ability to execute different treatments, from traditional and fractional rejuvenation, to various types of scar tissue, also deep, ultrafast vaporisations and other treatments which fall within various disciplines, completes the versatility of this new technology.
MOTUS PROTM is the latest evolution of the Motus line, Alexandrite laser and Nd:YAG, which has revolutionized the paradigms of epilation thanks to its high efficacy and very high comfort for the patient, also opening itself up to vascular treatments, up to the latest Made in the USA “MOVEO GLO”, which offers a complete face treatment, in the same session, to achieve optimal results at pigmentary, vascular and chrono-photo aging level. The “3 in 1” treatment with “GLO(W)” effect.
New design, more peak power, handled by a new software and mitigated by a new cooling system to carry forward the worldwide success in epilation signed by DEKA, are only a few of the novelties of the MOTUS PROTM technology.
Going back to CO2 Laser technology, SmartXide PROTM replicates the success of its predecessor, SmartXide DOT, the first fractional laser on the market, which has obtained success the world over, in particular in the United States, also known for periocular and blepharoplasty treatments.
Another important novelty is TOROTM, the laser device that the market had long been waiting for to act on more fronts: Spots, tattoos, rejuvenation, ranging from scar tissue to toning, all the way to the DEKAPeel treatment, to quickly intervene on dilated pores and obtain general improvement of cutaneous texture.
2 wavelengths, 1064 and 532 nm Q-Switched, and a third, 785nm, operating in the picosecond range, guarantee treatment efficacy and safety. TOROTM has been engineered especially for those skin types, among which Asian ones, which may benefit from this ultrafast coherent radiation, in terms of treatment efficacy and safety. By means of a pre-set database, which offers several clinical cases and a guided path throughout the various parameters which involve several targets (spot depth, tattoo color, typology of benign pigmented lesions, rejuvenation type and toning), TOROTM guides the physician, whilst guaranteeing treatment efficacy and safety.
Information on DEKA M.E.L.A.
DEKA M.E.L.A. is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.
This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients, and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.
DEKA means reaching perfection and excellence and it is “10”, the perfect number according to the philosopher and mathematician Pythagoras.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131482600/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
